Home › Companies › KYMERA THERAPEUTICS INC. › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and KYMERA THERAPEUTICS INC.’s Form 8-K, filed June 20, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 18, 2024: 6 items on KYMERA THERAPEUTICS INC.’s Form 8-K, filed June 20, 2024: 3 approved · 3 passed (calculated).
Notable dissent: 2 directors (12.2%, 11.8% against); 1 other board item (45.2% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore KYMERA THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are KYMERA THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 20, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Pamela Esposito, Ph.D. | 49,219,482 | -- | -- | 6,587,819 | 1,855,694 | 88% | Passed (calculated) | — |
| Elect Director: Gorjan Hrustanovic, Ph.D. | 48,998,105 | -- | -- | 6,809,196 | 1,855,694 | 88% | Passed (calculated) | — |
| Elect Director: Victor Sandor, M.D.C.M. | 51,424,753 | -- | -- | 4,382,548 | 1,855,694 | 92% | Passed (calculated) | — |
| 2. Non-Binding, Advisory Vote on Compensation of the Company's Named Executive Officers | 54,201,734 | 1,599,511 | 6,056 | -- | 1,855,694 | 97% | Approved | — |
| 3. Ratification of Appointment of the Company's Independent Registered Public Accounting Firm | 57,657,124 | 4,271 | 1,600 | -- | -- | 99.9% | Approved | — |
| 4. Approval of Amendment No | 30,565,165 | 25,232,934 | 9,202 | -- | 1,855,694 | 54.8% | Approved | — |
Source: KYMERA THERAPEUTICS INC., Form 8-K, filed with the SEC on June 20, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
182 asset managers disclosed a vote on at least one KYMERA THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
Description as filed by funds: To elect three class I directors to our Board of Directors, to serve until the 2027 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Gorjan Hrustanovic, Ph.D.
KYMERA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Gorjan Hrustanovic, Ph.D.”): 48,998,105 for, 6,809,196 withheld, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 88% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 69 asset managers below reported 16,166,074 for, 3,303,243 withheld, 29,852 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,141,763 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,948,344 | 0 | 0 | 0 | For |
| Fidelity | 541,923 | 0 | 0 | 2,223,395 | Mixed |
| State Street | 1,200,030 | 0 | 0 | 1,705 | For |
| BlackRock | 729,334 | 0 | 0 | 0 | For |
| Charles Schwab | 356,119 | 0 | 0 | 0 | For |
| MFS | 0 | 0 | 0 | 346,166 | Withhold |
| Hartford | 208,495 | 0 | 0 | 0 | For |
| JPMorgan | 165,857 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 153,457 | Withhold |
| First Trust | 0 | 0 | 0 | 135,718 | Withhold |
| Equitable | 76,356 | 0 | 0 | 40,750 | Mixed |
| John Hancock | 93,234 | 0 | 14,730 | 0 | Mixed |
| TIAA | 95,162 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 90,702 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 68,534 | Withhold |
| Northwestern Mutual | 63,533 | 0 | 0 | 0 | For |
| Neuberger Berman | 62,543 | 0 | 0 | 0 | For |
| Lincoln Financial | 31,900 | 0 | 0 | 22,632 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 52,703 | 0 | 0 | 0 | For |
| MML SERIES INVESTMENT FUND | 52,081 | 0 | 0 | 0 | For |
| Brighthouse | 39,390 | 0 | 0 | 11,855 | Mixed |
| American Century | 0 | 0 | 0 | 48,165 | Withhold |
| Transamerica | 47,121 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 0 | 41,033 | Withhold |
Showing the 25 largest of 69 asset managers. All 69 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
Description as filed by funds: To elect three class I directors to our Board of Directors, to serve until the 2027 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Pamela Esposito, Ph.D.
KYMERA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Pamela Esposito, Ph.D.”): 49,219,482 for, 6,587,819 withheld, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 88% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 69 asset managers below reported 16,167,644 for, 3,301,673 withheld, 29,852 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,141,763 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,948,344 | 0 | 0 | 0 | For |
| Fidelity | 541,923 | 0 | 0 | 2,223,395 | Mixed |
| State Street | 1,200,030 | 0 | 0 | 1,705 | For |
| BlackRock | 729,334 | 0 | 0 | 0 | For |
| Charles Schwab | 356,119 | 0 | 0 | 0 | For |
| MFS | 0 | 0 | 0 | 346,166 | Withhold |
| Hartford | 208,495 | 0 | 0 | 0 | For |
| JPMorgan | 165,857 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 153,457 | Withhold |
| First Trust | 0 | 0 | 0 | 135,718 | Withhold |
| Equitable | 76,356 | 0 | 0 | 40,750 | Mixed |
| John Hancock | 93,234 | 0 | 14,730 | 0 | Mixed |
| TIAA | 95,162 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 90,702 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 68,534 | Withhold |
| Northwestern Mutual | 63,533 | 0 | 0 | 0 | For |
| Neuberger Berman | 62,543 | 0 | 0 | 0 | For |
| Lincoln Financial | 31,900 | 0 | 0 | 22,632 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 52,703 | 0 | 0 | 0 | For |
| MML SERIES INVESTMENT FUND | 52,081 | 0 | 0 | 0 | For |
| Brighthouse | 39,390 | 0 | 0 | 11,855 | Mixed |
| American Century | 0 | 0 | 0 | 48,165 | Withhold |
| Transamerica | 47,121 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 0 | 41,033 | Withhold |
Showing the 25 largest of 69 asset managers. All 69 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
92% Majority: yes · of votes cast
Description as filed by funds: To elect three class I directors to our Board of Directors, to serve until the 2027 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Victor Sandor, M.D.C.M.
KYMERA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Victor Sandor, M.D.C.M.”): 51,424,753 for, 4,382,548 withheld, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 69 asset managers below reported 17,123,050 for, 2,367,250 withheld, 8,869 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,141,763 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,948,344 | 0 | 0 | 0 | For |
| Fidelity | 541,923 | 0 | 0 | 2,223,395 | Mixed |
| State Street | 1,201,605 | 0 | 0 | 130 | For |
| BlackRock | 729,334 | 0 | 0 | 0 | For |
| Charles Schwab | 356,119 | 0 | 0 | 0 | For |
| MFS | 346,166 | 0 | 0 | 0 | For |
| Hartford | 208,495 | 0 | 0 | 0 | For |
| JPMorgan | 165,857 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 153,457 | 0 | 0 | 0 | For |
| First Trust | 135,718 | 0 | 0 | 0 | For |
| Equitable | 76,356 | 0 | 0 | 40,750 | Mixed |
| John Hancock | 107,964 | 0 | 0 | 0 | For |
| TIAA | 95,162 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 90,702 | Withhold |
| AIG/SunAmerica | 68,534 | 0 | 0 | 0 | For |
| Northwestern Mutual | 63,533 | 0 | 0 | 0 | For |
| Neuberger Berman | 62,543 | 0 | 0 | 0 | For |
| Lincoln Financial | 50,642 | 0 | 0 | 3,890 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 52,703 | 0 | 0 | 0 | For |
| MML SERIES INVESTMENT FUND | 52,081 | 0 | 0 | 0 | For |
| Brighthouse | 51,245 | 0 | 0 | 0 | For |
| American Century | 48,165 | 0 | 0 | 0 | For |
| Transamerica | 47,121 | 0 | 0 | 0 | For |
| ProShares | 41,033 | 0 | 0 | 0 | For |
Showing the 25 largest of 69 asset managers. All 69 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
54.8% Approved · of votes cast
Description as filed by funds: TO APPROVE AN AMENDMENT TO THE KYMERA THERAPEUTICS, INC. 2020 STOCK OPTION AND INCENTIVE PLAN.
KYMERA THERAPEUTICS INC.’s own tally for this item (“4. Approval of Amendment No”): 30,565,165 for, 25,232,934 against — passed, per its Form 8-K filed June 20, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 4 – Approval of Amendment No. 1 to the Kymera Therapeutics, Inc. 2020 Stock Option and Incentive Plan The shareholders of the Company approved the amendment to the Kymera Therapeutics, Inc. 2020 Stock Option and Incentive Plan to amend the evergreen provision to provide that any of the Com…”
Support: 54.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 70 asset managers below reported 2,919,019 for, 16,575,774 against, 4,376 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,433,390 | 4,708,373 | 0 | 0 | Mixed |
| T. Rowe Price | 0 | 4,948,344 | 0 | 0 | Against |
| Fidelity | 0 | 2,765,318 | 0 | 0 | Against |
| State Street | 1,255 | 1,200,480 | 0 | 0 | Against |
| BlackRock | 0 | 729,334 | 0 | 0 | Against |
| Charles Schwab | 0 | 356,119 | 0 | 0 | Against |
| MFS | 0 | 346,166 | 0 | 0 | Against |
| Hartford | 208,495 | 0 | 0 | 0 | For |
| JPMorgan | 0 | 165,857 | 0 | 0 | Against |
| Direxion Shares ETF Trust | 0 | 153,457 | 0 | 0 | Against |
| First Trust | 0 | 135,718 | 0 | 0 | Against |
| Equitable | 0 | 117,106 | 0 | 0 | Against |
| John Hancock | 45,332 | 62,632 | 0 | 0 | Mixed |
| TIAA | 0 | 95,162 | 0 | 0 | Against |
| Dimensional | 0 | 90,702 | 0 | 0 | Against |
| AIG/SunAmerica | 0 | 68,534 | 0 | 0 | Against |
| Northwestern Mutual | 63,533 | 0 | 0 | 0 | For |
| Neuberger Berman | 0 | 62,543 | 0 | 0 | Against |
| Lincoln Financial | 0 | 54,532 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 0 | 52,703 | 0 | 0 | Against |
| MML SERIES INVESTMENT FUND | 52,081 | 0 | 0 | 0 | For |
| Brighthouse | 0 | 51,245 | 0 | 0 | Against |
| American Century | 0 | 48,165 | 0 | 0 | Against |
| Transamerica | 0 | 47,121 | 0 | 0 | Against |
| ProShares | 0 | 41,033 | 0 | 0 | Against |
Showing the 25 largest of 70 asset managers. All 70 are in the interactive database (link above).
Combines 9 wordings of this item as funds reported it.
97% Approved · of votes cast
Prior year: 96.6% for (June 15, 2023 meeting) ▲ 0.6 pts
Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of our named executive officers;
KYMERA THERAPEUTICS INC.’s own tally for this item (“2. Non-Binding, Advisory Vote on Compensation of the Company's Named Executive Officers”): 54,201,734 for, 1,599,511 against — passed, per its Form 8-K filed June 20, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Non-Binding, Advisory Vote on Compensation of the Company's Named Executive Officers The shareholders of the Company approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,141,763 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,948,344 | 0 | 0 | 0 | For |
| Fidelity | 2,765,318 | 0 | 0 | 0 | For |
| State Street | 1,201,249 | 486 | 0 | 0 | For |
| BlackRock | 729,334 | 0 | 0 | 0 | For |
| Charles Schwab | 356,119 | 0 | 0 | 0 | For |
| MFS | 0 | 346,166 | 0 | 0 | Against |
| Hartford | 208,495 | 0 | 0 | 0 | For |
| JPMorgan | 165,857 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 153,457 | 0 | 0 | 0 | For |
| First Trust | 135,718 | 0 | 0 | 0 | For |
| Equitable | 117,106 | 0 | 0 | 0 | For |
| John Hancock | 107,964 | 0 | 0 | 0 | For |
| TIAA | 95,162 | 0 | 0 | 0 | For |
| Dimensional | 90,702 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 68,534 | 0 | 0 | 0 | For |
| Northwestern Mutual | 63,533 | 0 | 0 | 0 | For |
| Neuberger Berman | 62,543 | 0 | 0 | 0 | For |
| Lincoln Financial | 54,532 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 52,703 | 0 | 0 | 0 | For |
| MML SERIES INVESTMENT FUND | 52,081 | 0 | 0 | 0 | For |
| Brighthouse | 51,245 | 0 | 0 | 0 | For |
| American Century | 0 | 48,165 | 0 | 0 | Against |
| Transamerica | 47,121 | 0 | 0 | 0 | For |
| ProShares | 41,033 | 0 | 0 | 0 | For |
Fund voting reports, all 70 managers: 19,071,765 for, 456,735 against, 1,184 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| New York Life | 11,000,000 | 0 | 0 | 0 | For |
| T. Rowe Price | 6,124,185 | 0 | 0 | 0 | For |
| BAKER BROS. ADVISORS LP | 5,995,928 | 0 | 0 | 0 | For |
| Atlas Venture Life Science Advisors, LLC | 5,377,362 | 0 | 0 | 0 | For |
| BVF INC/IL | 5,161,801 | 0 | 0 | 0 | For |
| Fidelity | 3,960,953 | 0 | 0 | 0 | For |
| Wellington | 3,744,501 | 0 | 0 | 0 | For |
| Avoro Capital Advisors LLC | 1,891,243 | 0 | 0 | 0 | For |
| State Street | 1,707,812 | 13,071 | 0 | 0 | For |
| Redmile Group, LLC | 1,663,267 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 1,505,750 | 0 | 0 | 0 | For |
| BlackRock | 1,302,220 | 7,803 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 579,979 | 0 | 0 | 0 | For |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 0 | 374,730 | 0 | 0 | Against |
| Charles Schwab | 356,119 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 0 | 328,291 | 0 | 0 | Against |
| UBS | 0 | 291,195 | 0 | 0 | Against |
| JPMorgan | 277,847 | 0 | 0 | 0 | For |
| Aquilo Capital Management, LLC | 253,428 | 0 | 0 | 0 | For |
| Northern Trust | 197,793 | 25 | 0 | 0 | For |
| Deep Track Capital, LP | 189,810 | 0 | 0 | 0 | For |
| DE Shaw | 166,546 | 0 | 0 | 0 | For |
| Rafferty Asset Management, LLC | 153,457 | 0 | 0 | 0 | For |
| JENNISON ASSOCIATES LLC | 148,163 | 0 | 0 | 0 | For |
| GREAT LAKES ADVISORS, LLC | 130,752 | 0 | 0 | 0 | For |
Institutional-manager reports, all 135 managers: 52,922,639 for, 1,346,566 against. Showing the 25 largest; every one is in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Prior year: 100.0% for (June 15, 2023 meeting) unchanged
Description as filed by funds: To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024; and
KYMERA THERAPEUTICS INC.’s own tally for this item (“3. Ratification of Appointment of the Company's Independent Registered Public Accounting Firm”): 57,657,124 for, 4,271 against — passed, per its Form 8-K filed June 20, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Ratification of Appointment of the Company's Independent Registered Public Accounting Firm The shareholders of the Company ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 70 asset managers below reported 19,528,500 for, 1,184 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,141,763 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,948,344 | 0 | 0 | 0 | For |
| Fidelity | 2,765,318 | 0 | 0 | 0 | For |
| State Street | 1,201,735 | 0 | 0 | 0 | For |
| BlackRock | 729,334 | 0 | 0 | 0 | For |
| Charles Schwab | 356,119 | 0 | 0 | 0 | For |
| MFS | 346,166 | 0 | 0 | 0 | For |
| Hartford | 208,495 | 0 | 0 | 0 | For |
| JPMorgan | 165,857 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 153,457 | 0 | 0 | 0 | For |
| First Trust | 135,718 | 0 | 0 | 0 | For |
| Equitable | 117,106 | 0 | 0 | 0 | For |
| John Hancock | 107,964 | 0 | 0 | 0 | For |
| TIAA | 95,162 | 0 | 0 | 0 | For |
| Dimensional | 90,702 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 68,534 | 0 | 0 | 0 | For |
| Northwestern Mutual | 63,533 | 0 | 0 | 0 | For |
| Neuberger Berman | 62,543 | 0 | 0 | 0 | For |
| Lincoln Financial | 54,532 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 52,703 | 0 | 0 | 0 | For |
| MML SERIES INVESTMENT FUND | 52,081 | 0 | 0 | 0 | For |
| Brighthouse | 51,245 | 0 | 0 | 0 | For |
| American Century | 48,165 | 0 | 0 | 0 | For |
| Transamerica | 47,121 | 0 | 0 | 0 | For |
| ProShares | 41,033 | 0 | 0 | 0 | For |
Showing the 25 largest of 70 asset managers. All 70 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 61,353,146 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 11.64% |
| 2 | T. Rowe Price | 8.07% |
| 3 | Fidelity | 4.51% |
| 4 | State Street | 1.96% |
| 5 | BlackRock | 1.19% |
| 6 | Charles Schwab | 0.58% |
| 7 | MFS | 0.56% |
| 8 | Hartford | 0.34% |
| 9 | JPMorgan | 0.27% |
| 10 | Direxion Shares ETF Trust | 0.25% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | New York Life | 17.93% |
| 2 | T. Rowe Price | 9.98% |
| 3 | BAKER BROS. ADVISORS LP | 9.77% |
| 4 | Atlas Venture Life Science Advisors, LLC | 8.76% |
| 5 | BVF INC/IL | 8.41% |
| 6 | Fidelity | 6.46% |
| 7 | Wellington | 6.10% |
| 8 | Avoro Capital Advisors LLC | 3.08% |
| 9 | State Street | 2.80% |
| 10 | Redmile Group, LLC | 2.71% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| T. Rowe Price | 6,332,012 | 10.32% | Form 13F, quarter ended March 31, 2024 |
| Entities affiliated with BVF Partners L.P. | 6,151,900 | 10.03% | Proxy statement (DEF 14A), proxy filed April 24, 2024 |
| Baker Bros. Advisors LP | 6,001,262 | 9.78% | Schedule 13D, filed August 22, 2024 |
| Entities affiliated with Baker Bros. Advisors LP | 5,997,706 | 9.78% | Proxy statement (DEF 14A), proxy filed April 24, 2024 |
| Felix Baker, Ph.D. | 5,997,706 | 9.78% | Proxy statement (DEF 14A), proxy filed April 24, 2024 |
| FMR (Fidelity) | 5,879,611 | 9.58% | Form 13F, quarter ended March 31, 2024 |
| Vanguard Group | 5,421,722 | 8.84% | Form 13F, quarter ended March 31, 2024 |
| Entities affiliated with Atlas Venture Partners | 5,377,362 | 8.76% | Proxy statement (DEF 14A), proxy filed April 24, 2024 |
| BlackRock | 4,365,448 | 7.12% | Form 13F, quarter ended March 31, 2024 |
| Wellington Management | 4,293,697 | 7.00% | Form 13F, quarter ended March 31, 2024 |
Percentages above are of 61,353,146 shares outstanding, as reported by KYMERA THERAPEUTICS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At KYMERA THERAPEUTICS INC.'s shareholder meeting held June 18, 2024, in the 2023-2024 proxy season, 182 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 1,552 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of our named executive officers; — KYMERA THERAPEUTICS INC.'s filing reports the proposal as approved, with 97% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: KYMERA THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 20, 2024.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from KYMERA THERAPEUTICS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
KYMERA THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Proxy Votes Now, “KYMERA THERAPEUTICS (KYMR) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/kymera-therapeutics-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.